ESC 2016

 
 
 

The Colosseum and Arch of Constantine in Rome. Photo by Konrad Zielinski.

ESC Congress 2016 took place August 27-31 in Rome, Italy.

 

Longer DAPT better for PAD, study suggests

HT Staff Read Article
Published: 09/03/16

aspirin_coated_Credit_Sage_Ross_230.jpg
Aspirin tablets
Photo by Sage Ross

A subanalysis of the PRODIGY study suggests a longer duration of dual antiplatelet therapy (DAPT) improves outcomes after percutaneous coronary intervention (PCI) for patients with peripheral arterial disease (PAD). Receiving long-term DAPT after PCI reduced the risk of atherothrombotic events and death in patients with PAD, without increasing the risk of actionable bleeding episodes. However, patients without PAD fared better with short-term DAPT. [Read Article]

Simple algorithm can rule out PE, team says

HT Staff Read Article
Published: 09/02/16

Pulmonary_embolism_CT_scan_of_Credit_Medical_College_of_Georgia_220.jpg
CTPA showing PE
Image courtesy of
Medical College of Georgia

A new study suggests the YEARS algorithm may provide a simple method for ruling out pulmonary embolism (PE) and therefore reduce the need for computed tomography pulmonary angiography (CTPA). “[The YEARS algorithm] can replace current diagnostic algorithms, which, although safe and accurate, are often not used in busy emergency departments because they are too complex,” said study investigator Tom Van der Hulle, MD. [Read Article]

Edoxaban appears comparable to standard therapy

HT Staff Read Article
Published: 09/02/16

warfarin_tablets.jpg
Warfarin tablets

The novel oral anticoagulant edoxaban is a feasible treatment option for patients with atrial fibrillation (AF) who need anticoagulation before cardioversion, according to researchers. Results of the ENSURE-AF trial suggest edoxaban is “an effective and safe alternative” to standard therapy with warfarin and enoxaparin and may allow for prompt cardioversion with transesophageal echocardiography (TEE), said Andreas Goette, MD. [Read Article]

Antidote to factor Xa inhibitors exhibits efficacy in patients with major bleeding

HT Staff Read Article
Published: 09/01/16

rivaroxaban-xarelto-tablets-prweb-240.png
Rivaroxaban tablets

Preliminary results from the ANNEXA-4 study suggest that andexanet alfa, an investigational antidote to factor Xa inhibitors, can be effective in patients with acute major bleeding. The drug reversed the anticoagulant effects of rivaroxaban, apixaban, and enoxaparin in this study, providing “excellent” or “good” hemostatic efficacy in 79% of patients over 12 hours. Thrombotic events occurred in 18% of patients, and 15% died during the 30-day follow-up period. [Read Article]

Antiplatelet drugs comparable in patients with AMI

HT Staff Read Article
Published: 09/01/16

ticagrelor_tablets_Credit_AstraZeneca_230.jpg
Ticagrelor tablets
Photo courtesy of AstraZeneca

The antiplatelet drugs prasugrel and ticagrelor produce similar early results in patients with acute myocardial infarction (AMI) treated with percutaneous coronary intervention (PCI), according to PRAGUE-18, the first randomized, head-to-head comparison of the drugs. “Our findings confirm previous indirect—non-randomized—comparisons of these 2 drugs, based on analyses of various registries,” said study investigator Petr Widimsky MD, DSc. [Read Article]

Rule identifies women at low risk of VTE recurrence

HT Staff Read Article
Published: 08/31/16

women-three-generations-230.jpg
Three generations
of women in a family

According to researchers, a clinical decision rule can identify women who, after their first unprovoked venous thromboembolism (VTE), have a low risk of VTE recurrence and might safely discontinue anticoagulant therapy. The researchers evaluated the HERDOO2 rule, which is named after the risk factors the rule employs to determine the likelihood of VTE recurrence, in the REVERSE II trial. Results from the trial were presented at ESC Congress 2016. [Read Article]

Antiplatelet monitoring doesn’t benefit high-risk patient group

HT Staff Read Article
Published: 08/31/16

doc_and_patient_older_woman_Credit_NIH_230.jpg
Doctor and patient
Photo courtesy of NIH

Results of the ANTARCTIC trial suggest that monitoring platelet function to individualize antiplatelet therapy does not improve outcomes for elderly patients stented for an acute coronary syndrome. These patients had a high risk of ischemic and bleeding complications, but the study showed no significant difference in the incidence of such complications between patients who were monitored and those who were not. [Read Article]

Two NOACs pose lower risk of ICH in real-world study

HT Staff Read Article
Published: 08/30/16

apixaban-eliquis-5mg_Pfizer_BMS_220.jpg
Apixaban tablets
Photo courtesy of Pfizer
and Bristol-Myers Squibb

Novel oral anticoagulants (NOACs) are as effective as warfarin for preventing stroke but may cause less intracranial hemorrhage (ICH) in patients with atrial fibrillation, according to research presented at ESC Congress 2016. For this study, investigators compared 3 NOACs—dabigatran, rivaroxaban, and apixaban—to warfarin in a “real-world” setting. They found that patients had a similar risk of stroke regardless of which drug they received. [Read Article]

Shorter DAPT appears safe for pts with type of DES

HT Staff Read Article
Published: 08/30/16

aspirin_bottle_Sage_Ross_230.jpg
Aspirin tablets
Photo by Sage Ross

A short-term course of dual antiplatelet therapy (DAPT) may be non-inferior to a longer course in patients who have a certain type of drug-eluting stent (DES), according to research presented at ESC Congress 2016. Patients in this study, known as NIPPON, had the Nobori bioabsorbable abluminal-coated stent and received 6 months or 18 months of DAPT, which consisted of aspirin plus clopidogrel or ticlopidine. [Read Article]

    {title}

    {icon} {author} Read Article
    Published: {pubDate}

    {summary}